Home > Healthcare > Healthcare IT > Telehealth > Digital Therapeutics Market

Digital Therapeutics Market Trends

  • Report ID: GMI5408
  • Published Date: Mar 2023
  • Report Format: PDF

Digital Therapeutics Market Trends

The surging prevalence of chronic conditions is projected to propel the demand globally. The substantial increase in the disease rates of chronic ailments such as obesity, diabetes, and cardiac conditions among others that lead to prolonged hospitalization, higher disease burden, and increased mortality rates are anticipated to prove beneficial for the industry growth. The incidence of diabetes is forecast to increase substantially in the elderly population aged 65 years or above. The management of such chronic diseases is generally multidimensional that comprises several aspects including the use of digital therapeutic software & devices thereby propelling the market expansion.
 

Digital therapeutics plays an anchoring role in chronic disease management as these solutions are proving to be one of the crucial factors in treatment. The rise in noncommunicable diseases (NCDs) and related mortality offers immense potential for market growth and opportunity for the market players to establish and penetrate the untapped market. Thus, the growing prevalence of chronic diseases is expected to expedite the digital therapeutics industry demand.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for digital therapeutics reached an estimated USD 6.5 billion in 2022 and is anticipated to garner over USD 104 billion in revenues by 2032, given the ability of digital therapeutics (DTx) to directly deliver medical interventions to patients using clinically evaluated evidence-based devices & software to prevent, manage, and treat several diseases and disorders.

The digital therapeutics industry share from the software segment is projected to grow at 31.7% CAGR between 2023 and 2032, attributed to the capability of digital software modalities in helping patients with medication adherence while offering personalized care enabling long-term behavioral change.

The digital therapeutics market size from the diabetes segment is set to expand at 31.0% CAGR from 2023 to 2032, driven by the surging requirement and an increased cognizance of the unique benefits of digital therapeutics in precisely managing diabetes.

Prominent enterprises in the digital therapeutics industry include Otsuka Holdings Co., Ltd., LifeScan Inc., Teladoc Health, Omada Health Inc., Pear Therapeutics, Inc., Propeller Health (ResMed), Teladoc Health, LifeScan, Inc., DarioHealth, Voluntis, My Sugr (Roche), and Virta Health Corp.

Digital Therapeutics Market Scope

Buy Now

Immediate Delivery Available

Premium Report Details

  • Base Year: 2022
  • Companies covered: 15
  • Tables & Figures: 192
  • Countries covered: 17
  • Pages: 169
 Download Free Sample